Method for preparing recombinant poliovirus-like particles
A poliovirus-like technology, which is applied in the field of related recombinant expression vectors and preparation of recombinant poliovirus-like particles, can solve the problems of lack of viral nucleic acid and non-infectivity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0071] The preparation of embodiment 1 virus particle
[0072] 1. Selection of expressed genes and optimal design of codons
[0073] The DNA sequence encoding the P1 protein and 3C protein of the poliomyelitis type I Mahoney strain refers to GeneBank: V01149.1, the amino acid sequence of the P1 protein is shown in SEQ ID NO:1, and the amino acid sequence of the 3C protein is shown in SEQ ID NO:2 .
[0074] Transform the wild-type DNA sequence encoding the P1 protein shown in SEQ ID NO:1 and the 3C protein shown in SEQ ID NO:2 in the type I Mahoney strain, and the codons used in Pichia pastoris are used as codons as possible , while avoiding transcription factor binding regions, repetitive sequences, and RNA advanced structures that may affect expression. After codon optimization, the sequence of the recombinant gene encoding the P1 protein is shown in SEQ ID NO:3, and the sequence of the recombinant gene encoding the 3C protein is shown in SEQ ID NO:4.
[0075] 2. Construct...
Embodiment 2
[0093] Antigen performance detection of embodiment 2 virus particle
[0094] 1. VLP Vaccine Preparation
[0095] The purified poliovirus-like particle protein was adsorbed with aluminum adjuvant (50 μg protein: 500 μg, aluminum adjuvant), and an immunogenic poliovirus vaccine was prepared.
[0096] 2. Determination of Immunogenicity of Poliovirus-like Particles
[0097]SPF grade BALB / c mice aged 6-8 weeks were selected and divided into 4 groups with 6 mice in each group. One group of mice was immunized with buffer solution (50mM PB pH7.0) containing aluminum adjuvant (as a negative control group), and the other three groups were immunized with 1 μg / mouse, 0.1 μg / mouse, and 0.01 μg / mouse (The immunization dose here refers to the quality of the virus-like particle protein amount), and the immunization was subcutaneously injected on the 0th and 14th days respectively, and a total of two immunizations were performed, and blood was collected two weeks after the second immunizatio...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


